Imugene Ltd has released a press release.
Appendix 4E & Annual Report to shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Imugene Receives Third PD1-VAXX Ethics Trial Approval
- Imugene Receives Clinical Guidance from US FDA for Vaxinia
- Imugene Receives Second PD1-VAXX Ethics Trial Approval
- Imugene Receives Ethics Approval to Start PD1-VAXX Trial
- Imugene HER-Vaxx Phase 2 Clinical Update
Later from Imugene
- Imugene Receives PD1-VAXX Ethics Trial Approval in USA
- Imugene Secures $5.7 million Option Underwriting Agreement
- Imugene Immunotherapy Combination Patent Granted in US
- Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
- Imugene HER Vaxx shows positive Overall Survival in trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene